Navigation Links
Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Date:11/5/2007

- Early study data from the two lowest dose groups show dose-dependent PSA

declines to date in all patients -

- Conference call to be held today at 8:30 A.M. Eastern time -

SAN FRANCISCO, Nov. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that its selective androgen receptor modulator, MDV3100, to date has reduced serum levels of prostate specific antigen (PSA), a marker of tumor growth, in the six patients enrolled in the first two dose groups of its ongoing Phase 1-2 trial in hormone refractory prostate cancer. PSA declines were seen in a dose-dependent manner in these patients. In the lowest dose group, after two months of treatment PSA levels declined 45 percent to 66 percent. PSA levels in the second lowest dose group declined 75 percent to 89 percent after the first month of treatment. MDV3100 has been well tolerated to date in both dose groups.

The ongoing Phase 1-2 trial is an open-label U.S. study enrolling prostate cancer patients who have failed standard hormonal therapies. The study is enrolling patients in up to seven dose groups of three patients each at escalating doses, with each group continuing treatment for at least three months barring any safety issues. The six patients enrolled to date comprise the two lowest dose groups, which to date have completed one and two months of treatment. Patient accrual for higher dose groups is ongoing. Once a maximum tolerated dose has been established, treatment at that dose level will be expanded to 20 patients. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression.

"While these results are still preliminary, the declines
'/>"/>

SOURCE Medivation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014  Remedy Informatics, the leading ... delivery and life sciences research, announced that it ... (NPF) to build the first-ever national patient registry ... and pancreatitis. "The National Pancreas Foundation ... that thoughtful and committed organizations can effect upon ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... , July 14, 2014  Celsion Corporation (NASDAQ: ... today that the Company will ring the NASDAQ Stock Market ... New York, NY . ... of the Celsion and EGEN management teams will participate in ... pm ET.  A live webcast will be available at ...
Breaking Medicine Technology:Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 2Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 3
... Feb. 22, 2011 Delcath Systems, Inc. (Nasdaq: ... received a "refusal to file" letter from the U.S. ... Application (NDA) for its proprietary chemosaturation system used in ... liver through the percutaneous intra-arterial administration of melphalan hydrochloride. ...
... Va., Feb. 21, 2011 MicroAire ... endoscopic treatment for carpal tunnel syndrome.  MicroAire,s new ... and blade assembly that allows surgeons to treat ... the patient,s wrist – thereby avoiding full open-hand ...
Cached Medicine Technology:Delcath Systems Receives Refusal to File Letter From FDA 2Delcath Systems Receives Refusal to File Letter From FDA 3Delcath Systems Receives Refusal to File Letter From FDA 4MicroAire Introduces New SlimLine™ ECTR Cannula 2
(Date:7/14/2014)... 2014 Follow us ... chromatography or UPLC is a new and ... that involves the use of extremely small-sized ... chromatographic compounds. This highly sensitive qualitative and ... analysis of chromatography samples. UPLC functions on ...
(Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up with ... and one-mile family fun walk. The run begins inside ... finishes inside Levi’s® Stadium. , Over the past five ... Mission City Community Fund. All proceeds benefit education, seniors ... athletes, part-time pavement-pounders and walkers are invited to help ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 T.E.N., ... relationship-marketing firm, announced today that nominations will be ... 2014 Information Security Executive® (ISE®) North America Awards. ... of the Year, which recognizes executives who have ... risk management, data-asset protection, regulatory compliance, privacy and ...
(Date:7/14/2014)... Many people are unhappy with their jawline. ... reduce a “double chin.” A new product that ... go under the knife. Jawflex is a double chin ... tightening the skin in that area and reducing the ... for facial exercise, double chin elimination and sagging jowls. ...
Breaking Medicine News(10 mins):Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... linked to hypertension years later, study finds , MONDAY, ... and Afghanistan who go into combat are more likely ... than those who serve in supporting roles, a new ... appeared to be a unique risk factor for newly ...
... Surging obesity rates have reversed gains, study finds , MONDAY, ... heart disease may be on the wane, experts say, with ... are now in the clear when it comes to heart ... bear much of the blame for the downturn, the researchers ...
... Analysis notes tamoxifen, raloxifene can up chances of other ... Medications given to women at high risk for developing ... drugs carry other health risks, a new analysis suggests. ... at numerous published studies, including randomized clinical trials and ...
... Global meeting ... ... Scientists and Technologists, , ,WHAT: 21st International Radon Symposium , , ,WHEN: September 20-23, ... Station, , ,WHY: Radon remains a serious, global health threat and remains the ...
... 14 Misonix, Inc. (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... who wishes to remain anonymous, donated the majority of the ... NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement ...
... , LOS ALTOS, Calif., Sept. 14 ... Higgins, PhD has been named Chief Operating ... as InteKrin,s Chief Scientific Officer after joining the Company earlier ... has had increasingly broad operational and strategic responsibility in key ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3Health News:InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer 2
... Maxim knee system's curved-on-curved articulation maintains ... excellent sizing options for better patient ... alloy plasma spray porous coating, which ... own ArCom processed polyethylene is used ...
... posterior stabilized knee has an advanced ... flange mates with both resurfacing and ... precise, repeatable kinematics and fit with ... reduce wear. Constant cutting guide peg ...
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Medicine Products: